Company News – Ymmunbio

Ymmunobio Achieves Major Preclinical Milestone with YB-800 ADCs

Ymmunobio — Sat, 19 Apr 2025 09:58:39 +0000

RIEHEN, Switzerland, April 18, 2025 /PRNewswire/ — Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer therapeutics, is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs.

Read the full report here.

Ymmunobio & Paul-Scherrer Institute win Innosuisse grant to develop radiopharmaceutical with YB-800

Ymmunobio — Sun, 26 Jan 2025 14:06:14 +0000

We are excited to report that our collaboration with the PSI, supported by an Innosuisse Grant, is kicking off now! Sonne there will be the first results to be reported about our radio pharmaceutical project.

Check out the full report here: https://lnkd.in/eZWU49gD

We are very proud to announce our 3rd place achievement at the Prix Galien USA Awards!

Ymmunobio — Thu, 14 Nov 2024 14:27:42 +0000

We are honored to be nominated and thrilled to secure 3rd place at this presigious event! Although typically only the winner is announced, a Prix Galien Foundation team member remembered Ymmunobio because of our unique name and that “Y” in front – it sparked a conversation and a smile!

Read the full article here: https://www.linkedin.com/feed/update/urn:li:activity:7262811531346685953

A big thank you to everyone who helped make this night memorable, and here’s to many more innovative milestones ahead!

Countdown to the Prix Galien Awards: Showcasing Science-Driven Innovation in NYC!

Ymmunobio — Wed, 30 Oct 2024 17:01:00 +0000

In just two weeks Ymmunobio is heading to New York for the prestigious Prix Galien USA Awards, where we’ll be competing in the “Best Startup” category!

It’s an incredible honor to be recognized by such an esteemed foundation that celebrates innovation and excellence in life sciences and healthcare.

Read the full post on LinkedIn →

Ymmunobio and EVIIVE announce collaboration to develop advanced liquid biopsy for detecting NPTXR in cancer patients

Ymmunobio — Fri, 21 Jun 2024 22:05:30 +0000

We are thrilled to announce a groundbreaking partnership between Ymmunobio and EVIIVE to advance the future of cancer diagnostics!

Together, we are developing an innovative liquid biopsy technology using extracellular vesicles (EVs), enhancing precision in disease detection and monitoring. Our joint efforts will leverage Ymmunobio’s cutting-edge biotechnological expertise and EVIIVE’s advanced diagnostic platforms to create a revolutionary tool in the fight against cancer.

Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.

Stay tuned for more updates as we work towards a brighter, healthier future!

Read the full press release here:

https://www.einpresswire.com/article/719981774/ymmunobio-and-eviive-announce-collaboration-to-develop-advanced-liquid-biopsy-for-detecting-nptxr-in-cancer-patients

Ymmunobio is proud to announce our ASCO publication on YB-800

Ymmunobio — Mon, 03 Jun 2024 22:07:00 +0000

We are thrilled to announce that Ymmunobio’s abstract has been published in the American Society of Clinical Oncology (ASCO) annual conference publications:

“YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first-in-class antibody-drug conjugate (ADC) as a novel therapeutic intervention in gastro-intestinal cancers”

The full publication can be found here.

The abstract highlights using a fully humanized monoclonal antibody, YB-800, directed against the human neuronal pentraxin receptor (NPTXR). The expression of NPTXR has been associated with disease progression in several GI Cancers, including gastric, esophageal, colorectal, pancreatic, bladder and liver as well as breast and thyroid cancer. These findings provided a strong rationale for the design of a YB-800 based ADC, offering a novel therapeutic intervention option for patients with high unmet medical needs.

We are thrilled to contribute to the advancement of cancer treatment and dedicated to pursuing innovative therapies that can significantly impact patient care.

Global Business Report interviews Ymmunobio CEO Peter Schiemann

Ymmunobio — Sat, 11 May 2024 22:22:00 +0000

Check out the latest GBR Connect Series interview with our CEO and Co-Founder
Peter Schiemann, where he talks about the latest Ymmunobio Developments and the key focus areas for 2024 to establish a positive proof of concept with our ADC candidate YB800 targeting a new receptor in GI Cancers.

You can access the full interview here: Global Business Reports – Peter Schiemann (gbreports.com )

Ymmunobio has been selected for the Venture Leaders Biotech 2024!

Ymmunobio — Sat, 11 May 2024 22:09:00 +0000

We are very proud to announce that Ymmunobio is one of 10 Start-ups that has been selected for the Venture Leaders Biotech 2024.

Selected from over 70 applicants by a jury of investors and biotech experts, Ymmunobio will join the roadshow in Boston, one of the world’s most important life science hubs.
From May 13th – 17th 2024, the roadshow will connect the participants with international investors and industry leaders, accelerating their ventures’ expansion the US.

Go to the Venture Leaders Biotech Website for more information.

Successful completion of the seed funding round for Ymmunobio!

Ymmunobio — Fri, 10 Nov 2023 22:25:00 +0000

Basel, Switzerland & Princeton, NJ, USA, November 10, 2023 ─ Ymmunobio, a global preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies, has closed its round of seed funding.

Ymmunobio has raised $1.4M to progress both assets, YB-200 and YB-800, to IND-enabling studies.

YB-200, is a humanized anti CEACAM1 antibody with a new mechanism of action, which includes a direct immune agonistic effect on immune cells in addition to the known check-point inhibitor effect.

YB-800 is a first in class humanized antibody targeting the Neuronal Pentraxin Receptor (NPTXR), which is selectively expressed on tumor cells. Both antibodies are developed for treatment of gastrointestinal tumors. YB-200 has received orphan drug status by the US FDA for the treatment of liver cancer in February 2023.

Caroline Germa, MD, board member of Ymmunobio, CMO of Transcenta and former head of early oncology development of Astra Zeneca: “Developing new and first in class antibodies for the treatment of cancers is a critical need. Available preclinical data of YB-200 and YB-800 show that each has the potential to be a first- and/or best-in-class therapy across a broad range of solid tumors.”

Ymmunobio would like to thank its private investors for enabling the advancement of the development of YB-200 and YB-800 to IND enabling studies.

ABOUT YMMUNOBIO

Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making significant progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.

Investor Relations:

Christian Germa, CFO

Contact : chris.p.germa@ymmuno.bio

2023 CIMT Annual Meeting Poster Presentation

Ymmunobio — Tue, 05 Sep 2023 23:00:00 +0000

YB-200, a novel IgG1 antibody targeting CEACAM1/5, induces complete response in syngeneic liver Hepa1-6 tumor-bearing mice and modulates the immune response

Download full poster:

CIMT 2023 poster (PDF)